As a Venture Partner at adMare, Canada’s global life sciences venture, Dr. Crawford is responsible for overseeing and advancing a portfolio of drug development and commercialization projects through management of multi-disciplinary scientific and business teams. Prior to assuming this role, he was VP of Scientific Operations after joining the organization as Head of Medicinal Chemistry in 2008.
Previously, from 1999-2007, he held a series of increasingly-senior positions at AnorMED Inc. leading to Manager of the Development Chemistry Group. Notably he led the process development and transfer to a GMP manufacturer for clinical manufacture and process validation for commercial use for plerixafor, which now generates over $150 million annually in global sales as Mozobil. Concurrent to this role, he was also an interdisciplinary project team leader for a clinical-stage anti-HIV therapeutic, which is now in clinical trials for oncology as Mavorixafor with X4 Pharmaceuticals. In addition to his experience at AnorMED, Dr. Crawford also developed novel antibacterial agents in his role of Senior Scientist, Medicinal Chemistry at Microcide Pharmaceuticals Inc. based in Mountain View, California.
Dr. Crawford received his B.Sc. in chemistry/biochemistry in 1991, and a PhD in organic chemistry in 1996 from the University of Victoria (Canada). He then conducted post-doctoral research in organic synthesis at the Ohio State University from 1996-1997.